REGENXBIO reported a net loss of $67.1 million for Q4 2025, despite a 43% increase in revenue driven by higher license and royalty income. The company faced regulatory setbacks with clinical holds on RGX-111 and RGX-121, but continues to advance its pivotal trials for RGX-202 and sura-vec with a cash runway extending into early 2027.

REGENXBIO reported $89.0 million in revenue and a net income of $6.1 million for Q1 2025, reversing last year’s net loss due to a $71.8 million boost from a licensing deal with Nippon Shinyaku.

REGENXBIO reported Q4 2024 revenue of $21.2 million, a slight decrease from the previous year, primarily due to lower royalty revenues. Net loss for the quarter improved to $51.2 million compared to $62.9 million in Q4 2023. The company ended the year with $244.9 million in cash and expects its cash runway to extend into the second half of 2026. R&D expenses were $50.4 million, reflecting continued investment in gene therapy programs.

REGENXBIO reported a net loss of $59.6 million for the third quarter of 2024, with revenues of $24.2 million. The company's cash, cash equivalents, and marketable securities totaled $278.6 million as of September 30, 2024, expected to fund operations into 2026. Key advancements include progress in the RGX-202 and ABBV-RGX-314 trials, and initiation of the BLA submission for RGX-121.